Navigation Links
Announcing the 1st IOF-ESCEO Pre-Clinical Symposium
Date:6/24/2010

The International Osteoporosis Foundation (IOF) is pleased to announce the inaugural IOF-ESCEO Pre-Clinical Symposium a new forum for the best pre-clinical and translational science in bone biology to be held from March 22-23, 2011, immediately preceding the European Congress on Osteoporosis and Osteoarthritis (ECCEO11-IOF) in Valencia .

The Symposium will be chaired by Gerard Karsenty, Professor and Chair, Genetics & Development, Columbia University MC one of the world's leading scientists from the bone biology arena. The Symposium will feature four hours of lectures by invited key opinion leaders, held in an informal setting to encourage discussion and stimulating interaction. Most importantly, the Symposium will provide an outstanding opportunity for young investigators to showcase their latest research in over eight hours of oral presentations, selected from the highest ranked abstracts. In order to support the travel costs of researchers, IOF and ESCEO will award 500 Euro travel grants to the scientists selected for oral presentations.

Pure science no distractions:

Scientists engaged in pre-clinical research in osteoporosis, osteoarthritis and related metabolic bone diseases are invited to take this opportunity to present and discuss their latest research findings with other investigators and key opinion leaders. The organizers intend to create a uniquely intimate, stimulating environment focused purely on science with no exhibitions or other distractions.

Registrants to the 1st Pre-Clinical Symposium may opt to attend the ECCEO11-IOF from March 23-26, 2011 at a significantly reduced registration rate.


'/>"/>

Contact: L. Misteli
news@iofbonehealth.org
International Osteoporosis Foundation
Source:Eurekalert

Page: 1

Related biology news :

1. IUs Carlson among team of scientists announcing new species of prehistoric man
2. New dinosaur rears its head; U-M researchers part of team announcing find
3. Announcing IOF Regionals 1st Asia-Pacific osteoporosis meeting
4. Announcing the new Journal of Integrated Pest Management
5. A missing enzyme conveys major heart protection in pre-clinical work
6. Alzheimers disease therapeutic prevents long-term damage from TBI in pre-clinical studies
7. Prosthetic vein valve designed to direct blood flow shows promising pre-clinical results
8. Singulex Teams With Wyeth Pharmaceuticals to Translate Pre-Clinical Biomarker Research Into Clinical Study Design
9. National Eye Institute hosts Translational Research and Vision Symposium
10. Momentum builds after 4th International Symposium on Pet Contraception
11. Symposium: Implications for the future of personalize medicine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2016)... --  EyeLock LLC , a market leader of iris-based ... IoT Center of Excellence in Austin, Texas ... embedded iris biometric applications. EyeLock,s iris authentication ... with unmatched biometric accuracy, making it the most proven ... platform uses video technology to deliver a fast and ...
(Date:4/28/2016)... and BANGALORE, India , April 28, ... Systems, a product subsidiary of Infosys (NYSE: INFY ... announced a global partnership that will provide end ... use mobile banking and payment services.      (Logo: ... key innovation area for financial services, but it also plays ...
(Date:4/19/2016)... , UAE, April 20, 2016 ... be implemented as a compact web-based "all-in-one" system solution ... the biometric fingerprint reader or the door interface with ... of modern access control systems. The minimal dimensions of ... ID readers into the building installations offer considerable freedom ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... DIEGO , June 24, 2016 ... more sensitively detects cancers susceptible to PARP inhibitors ... circulating tumor cells (CTCs). The new test has ... HRD-targeted therapeutics in multiple cancer types. ... targeting DNA damage response pathways, including PARP, ATM, ...
(Date:6/23/2016)... CAMBRIDGE, Mass. , June 23, 2016 /PRNewswire/ ... the development of novel compounds designed to target ... compound, napabucasin, has been granted Orphan Drug Designation ... in the treatment of gastric cancer, including gastroesophageal ... cancer stemness inhibitor designed to inhibit cancer stemness ...
(Date:6/23/2016)... Calif. , June 23, 2016  The Prostate Cancer Foundation ... increasingly precise treatments and faster cures for prostate cancer. Members of the Class ... across 15 countries. Read More About the Class of ... ... ...
(Date:6/23/2016)... ... June 23, 2016 , ... In a new case report published today in ... patient who developed lymphedema after being treated for breast cancer benefitted from an injection ... for dealing with this debilitating, frequent side effect of cancer treatment. , ...
Breaking Biology Technology: